Financhill
Sell
44

ADPT Quote, Financials, Valuation and Earnings

Last price:
$7.88
Seasonality move :
11.6%
Day range:
$7.33 - $7.86
52-week range:
$2.48 - $9.01
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.07x
P/B ratio:
5.41x
Volume:
1.9M
Avg. volume:
2.3M
1-year change:
186.05%
Market cap:
$1.1B
Revenue:
$179M
EPS (TTM):
-$1.09

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ADPT
Adaptive Biotechnologies
$42.1M -$0.31 0.6% -9.85% $9.71
NBY
NovaBay Pharmaceuticals
$3M -$0.24 14.03% -95.43% $0.85
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
OGEN
Oragenics
-- -- -- -- $1.00
PTN
Palatin Technologies
-- -$0.17 -- -67.93% --
TOVX
Theriva Biologics
-- -$5.50 -- -8.25% $6.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ADPT
Adaptive Biotechnologies
$7.38 $9.71 $1.1B -- $0.00 0% 6.07x
NBY
NovaBay Pharmaceuticals
$0.58 $0.85 $3.4M -- $0.00 0% 0.15x
NNVC
Nanoviricides
$1.33 -- $20.9M -- $0.00 0% --
OGEN
Oragenics
$0.19 $1.00 $4.2M -- $0.00 0% 1.21x
PTN
Palatin Technologies
$0.20 -- $5.1M -- $0.00 0% --
TOVX
Theriva Biologics
$1.43 $6.00 $4M -- $0.00 0% 0.63x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ADPT
Adaptive Biotechnologies
-- 3.533 -- 2.69x
NBY
NovaBay Pharmaceuticals
4.54% 0.451 1.51% 0.75x
NNVC
Nanoviricides
-- 1.928 -- --
OGEN
Oragenics
-- 3.461 -- --
PTN
Palatin Technologies
-- 0.220 -- --
TOVX
Theriva Biologics
-- -1.635 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ADPT
Adaptive Biotechnologies
$29.4M -$33.8M -63.77% -63.77% -64.82% -$12.6M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
NNVC
Nanoviricides
-- -$2.1M -- -- -- -$2.2M
OGEN
Oragenics
-- -$3.4M -- -- -- -$2M
PTN
Palatin Technologies
-- -- -- -- -- --
TOVX
Theriva Biologics
-- -$4.6M -- -- -- -$4.7M

Adaptive Biotechnologies vs. Competitors

  • Which has Higher Returns ADPT or NBY?

    NovaBay Pharmaceuticals has a net margin of -70.99% compared to Adaptive Biotechnologies's net margin of -49.65%. Adaptive Biotechnologies's return on equity of -63.77% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    ADPT
    Adaptive Biotechnologies
    61.98% -$0.23 $202.5M
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About ADPT or NBY?

    Adaptive Biotechnologies has a consensus price target of $9.71, signalling upside risk potential of 31.63%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 47.26%. Given that NovaBay Pharmaceuticals has higher upside potential than Adaptive Biotechnologies, analysts believe NovaBay Pharmaceuticals is more attractive than Adaptive Biotechnologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    ADPT
    Adaptive Biotechnologies
    3 1 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is ADPT or NBY More Risky?

    Adaptive Biotechnologies has a beta of 1.728, which suggesting that the stock is 72.844% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

  • Which is a Better Dividend Stock ADPT or NBY?

    Adaptive Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptive Biotechnologies pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ADPT or NBY?

    Adaptive Biotechnologies quarterly revenues are $47.5M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Adaptive Biotechnologies's net income of -$33.7M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Adaptive Biotechnologies's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptive Biotechnologies is 6.07x versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ADPT
    Adaptive Biotechnologies
    6.07x -- $47.5M -$33.7M
    NBY
    NovaBay Pharmaceuticals
    0.15x -- $2.4M -$1.2M
  • Which has Higher Returns ADPT or NNVC?

    Nanoviricides has a net margin of -70.99% compared to Adaptive Biotechnologies's net margin of --. Adaptive Biotechnologies's return on equity of -63.77% beat Nanoviricides's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ADPT
    Adaptive Biotechnologies
    61.98% -$0.23 $202.5M
    NNVC
    Nanoviricides
    -- -$0.14 --
  • What do Analysts Say About ADPT or NNVC?

    Adaptive Biotechnologies has a consensus price target of $9.71, signalling upside risk potential of 31.63%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 387.4%. Given that Nanoviricides has higher upside potential than Adaptive Biotechnologies, analysts believe Nanoviricides is more attractive than Adaptive Biotechnologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    ADPT
    Adaptive Biotechnologies
    3 1 0
    NNVC
    Nanoviricides
    0 0 0
  • Is ADPT or NNVC More Risky?

    Adaptive Biotechnologies has a beta of 1.728, which suggesting that the stock is 72.844% more volatile than S&P 500. In comparison Nanoviricides has a beta of 0.927, suggesting its less volatile than the S&P 500 by 7.287%.

  • Which is a Better Dividend Stock ADPT or NNVC?

    Adaptive Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptive Biotechnologies pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ADPT or NNVC?

    Adaptive Biotechnologies quarterly revenues are $47.5M, which are larger than Nanoviricides quarterly revenues of --. Adaptive Biotechnologies's net income of -$33.7M is lower than Nanoviricides's net income of -$2M. Notably, Adaptive Biotechnologies's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptive Biotechnologies is 6.07x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ADPT
    Adaptive Biotechnologies
    6.07x -- $47.5M -$33.7M
    NNVC
    Nanoviricides
    -- -- -- -$2M
  • Which has Higher Returns ADPT or OGEN?

    Oragenics has a net margin of -70.99% compared to Adaptive Biotechnologies's net margin of --. Adaptive Biotechnologies's return on equity of -63.77% beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ADPT
    Adaptive Biotechnologies
    61.98% -$0.23 $202.5M
    OGEN
    Oragenics
    -- -$0.27 --
  • What do Analysts Say About ADPT or OGEN?

    Adaptive Biotechnologies has a consensus price target of $9.71, signalling upside risk potential of 31.63%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 415.46%. Given that Oragenics has higher upside potential than Adaptive Biotechnologies, analysts believe Oragenics is more attractive than Adaptive Biotechnologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    ADPT
    Adaptive Biotechnologies
    3 1 0
    OGEN
    Oragenics
    0 1 0
  • Is ADPT or OGEN More Risky?

    Adaptive Biotechnologies has a beta of 1.728, which suggesting that the stock is 72.844% more volatile than S&P 500. In comparison Oragenics has a beta of 0.868, suggesting its less volatile than the S&P 500 by 13.16%.

  • Which is a Better Dividend Stock ADPT or OGEN?

    Adaptive Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptive Biotechnologies pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ADPT or OGEN?

    Adaptive Biotechnologies quarterly revenues are $47.5M, which are larger than Oragenics quarterly revenues of --. Adaptive Biotechnologies's net income of -$33.7M is lower than Oragenics's net income of -$3.3M. Notably, Adaptive Biotechnologies's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptive Biotechnologies is 6.07x versus 1.21x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ADPT
    Adaptive Biotechnologies
    6.07x -- $47.5M -$33.7M
    OGEN
    Oragenics
    1.21x -- -- -$3.3M
  • Which has Higher Returns ADPT or PTN?

    Palatin Technologies has a net margin of -70.99% compared to Adaptive Biotechnologies's net margin of --. Adaptive Biotechnologies's return on equity of -63.77% beat Palatin Technologies's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ADPT
    Adaptive Biotechnologies
    61.98% -$0.23 $202.5M
    PTN
    Palatin Technologies
    -- -- --
  • What do Analysts Say About ADPT or PTN?

    Adaptive Biotechnologies has a consensus price target of $9.71, signalling upside risk potential of 31.63%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 3489.74%. Given that Palatin Technologies has higher upside potential than Adaptive Biotechnologies, analysts believe Palatin Technologies is more attractive than Adaptive Biotechnologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    ADPT
    Adaptive Biotechnologies
    3 1 0
    PTN
    Palatin Technologies
    0 0 0
  • Is ADPT or PTN More Risky?

    Adaptive Biotechnologies has a beta of 1.728, which suggesting that the stock is 72.844% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

  • Which is a Better Dividend Stock ADPT or PTN?

    Adaptive Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptive Biotechnologies pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ADPT or PTN?

    Adaptive Biotechnologies quarterly revenues are $47.5M, which are larger than Palatin Technologies quarterly revenues of --. Adaptive Biotechnologies's net income of -$33.7M is higher than Palatin Technologies's net income of --. Notably, Adaptive Biotechnologies's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptive Biotechnologies is 6.07x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ADPT
    Adaptive Biotechnologies
    6.07x -- $47.5M -$33.7M
    PTN
    Palatin Technologies
    -- -- -- --
  • Which has Higher Returns ADPT or TOVX?

    Theriva Biologics has a net margin of -70.99% compared to Adaptive Biotechnologies's net margin of --. Adaptive Biotechnologies's return on equity of -63.77% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ADPT
    Adaptive Biotechnologies
    61.98% -$0.23 $202.5M
    TOVX
    Theriva Biologics
    -- -$1.60 --
  • What do Analysts Say About ADPT or TOVX?

    Adaptive Biotechnologies has a consensus price target of $9.71, signalling upside risk potential of 31.63%. On the other hand Theriva Biologics has an analysts' consensus of $6.00 which suggests that it could grow by 319.58%. Given that Theriva Biologics has higher upside potential than Adaptive Biotechnologies, analysts believe Theriva Biologics is more attractive than Adaptive Biotechnologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    ADPT
    Adaptive Biotechnologies
    3 1 0
    TOVX
    Theriva Biologics
    0 0 0
  • Is ADPT or TOVX More Risky?

    Adaptive Biotechnologies has a beta of 1.728, which suggesting that the stock is 72.844% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.169, suggesting its more volatile than the S&P 500 by 16.92%.

  • Which is a Better Dividend Stock ADPT or TOVX?

    Adaptive Biotechnologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adaptive Biotechnologies pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ADPT or TOVX?

    Adaptive Biotechnologies quarterly revenues are $47.5M, which are larger than Theriva Biologics quarterly revenues of --. Adaptive Biotechnologies's net income of -$33.7M is lower than Theriva Biologics's net income of -$4.4M. Notably, Adaptive Biotechnologies's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adaptive Biotechnologies is 6.07x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ADPT
    Adaptive Biotechnologies
    6.07x -- $47.5M -$33.7M
    TOVX
    Theriva Biologics
    0.63x -- -- -$4.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Should You Buy Alibaba Stock Despite the Risks?
Should You Buy Alibaba Stock Despite the Risks?

Markets rebounded slightly after U.S. President Donald Trump announced a…

Why Is Intel Struggling Against AMD?
Why Is Intel Struggling Against AMD?

Due to its disappointing reports, so-so management, and lack of…

Will PayPal Stock Recover or Keep Sliding?
Will PayPal Stock Recover or Keep Sliding?

Payments platform behemoth PayPal Holdings, Inc. (NASDAQ:PYPL) is going through…

Stock Ideas

Buy
56
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 34x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 32x

Sell
49
Is NVDA Stock a Buy?

Market Cap: $2.5T
P/E Ratio: 35x

Alerts

Buy
71
PEGA alert for Apr 24

Pegasystems [PEGA] is up 3.13% over the past day.

Buy
67
SMMT alert for Apr 24

Summit Therapeutics [SMMT] is up 10.38% over the past day.

Sell
36
ENPH alert for Apr 24

Enphase Energy [ENPH] is up 1.44% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock